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Of the eight human genes implicated in xeroderma
pigmentosum, defects in XPG produce some of the
most clinically diverse symptoms. These range from
mild freckling to severe skeletal and neurologic
abnormalities characteristic of Cockayne syndrome.
Mildly affected xeroderma pigmentosum group G
patients have diminished XPG endonuclease activity
in nucleotide excision repair, whereas severely
affected xeroderma pigmentosum group G/
Cockayne syndrome patients produce truncated
XPG proteins that are unable to function in either
nucleotide excision repair or the transcription-
coupled repair of oxidative lesions. The ®rst two
xeroderma pigmentosum group G patients, XP2BI
and XP3BR, were reported before the relationship
between xeroderma pigmentosum group G and
Cockayne syndrome was appreciated. Here we pro-
vide evidence that both patients produce truncated
proteins from one XPG allele. From the second
allele, XP2BI generates full-length XPG of 1186
amino acids containing a single L858P substitution
that has reduced stability and greatly impaired endo-
nuclease activity. In XP3BR, a single base deletion
and alternative splicing at a rare noncanonical AT±
AC intron produces a 1185 amino acid protein con-
taining 44 internal non-XPG residues. This protein is
stably expressed but it also has greatly impaired
endonuclease activity. These four XPG products can
thus account for the severe ultraviolet sensitivity of
XP2BI and XP3BR ®broblasts. These cells, unlike
those from xeroderma pigmentosum group G/
Cockayne syndrome patients, are capable of limited
transcription-coupled repair of oxidative lesions. Our
results suggest that the L858P protein in XP2BI and
the almost full-length XPG protein in XP3BR are
responsible for this activity and for the absence of
severe early onset Cockayne syndrome symptoms in
these patients. Key words: Cockayne syndrome/DNA
repair/nucleotide excision repair/transcription-coupled
repair. J Invest Dermatol 118:344±351, 2002
X
PG is one of eight human genes causally implicated
in xeroderma pigmentosum (XP), a rare autosomal
recessive disorder characterized by acute sun sensi-
tivity, a high incidence of skin cancers in sun-
exposed areas and, in some patients, progressive
neurologic abnormalities (Cleaver and Kraemer, 1995; Rapin et al,
2000). The products of seven of these genes (XPA±XPG) are
involved in nucleotide excision repair (NER), the important DNA
repair pathway that removes damage caused by ultraviolet (UV)
light and many chemical agents. The enzymatic role of the
133 kDa XPG protein in this pathway is now well established: it is
a structure-speci®c endonuclease that cuts the damaged DNA
strand 3¢ to the lesion near the junction between the unpaired
damaged strand and downstream undamaged duplex DNA
(O'Donovan et al, 1994a; Matsunaga et al, 1995). XPG also has a
noncatalytic role in NER: its presence is required in the incision
complex to permit the ERCC1-XPF heterodimer to make the
5¢-cut (Wakasugi et al, 1997; Constantinou et al, 1999).
The group G form of XP is very rare and clinically very
heterogeneous. The 10 reported cases range from mildly affected
young adults whose XP diagnosis is not at all obvious (Ichihashi
et al, 1985; Norris et al, 1987) to patients who died in infancy or
early childhood with symptoms characteristic of a second disorder,
Cockayne syndrome (CS) (Jaeken et al, 1989; Vermeulen et al,
1993; Hamel et al, 1996; Moriwaki et al, 1996; Zafeiriou et al,
2001). These include neuronal demyelination, mental retardation,
microcephaly, skeletal and retinal abnormalities, and dental caries,
but no predisposition to cancer (Nance and Berry, 1992; Rapin et al,
2000). At ®rst sight, XP-G also seems to be a not particularly cancer
prone condition as only two of the reported 10 cases developed
skin cancer; however, four XP-G individuals suffered from severe
early onset CS and received very little UV exposure before their
early demise (Jaeken et al, 1989; Hamel et al, 1996; Moriwaki et al,
1996), and two others have very low but signi®cant NER activity
that can account for their lack of severe XP symptoms
(Constantinou et al, 1999).
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In some very rare cases, some CS individuals have been found to
carry mutations in the XPB and XPD genes. These genes encode
the helicase subunits of TFIIH, a multisubunit factor that is essential
for both NER and transcription by RNA polymerase II (Frit et al,
1999). Most CS patients, however, belong to the CS-A and CS-B
complementation groups and possess no XP overlap. The functions
of the corresponding CSA and CSB proteins are not yet established
but cells from these patients are defective in transcription-coupled
repair (TCR), a process whereby DNA damage is preferentially
removed from the transcribed strand of active genes (Mellon et al,
1987; van Hoffen et al, 1993). Although initially described for the
removal of UV damage, and therefore considered to be a
subpathway of NER, TCR is now recognized as being a more
general phenomenon that operates on other kinds of DNA lesions,
including oxidative DNA damage (Leadon and Cooper, 1993;
Cooper et al, 1997; Nouspikel et al, 1997; Le Page et al, 2000).
A common pattern has emerged from molecular genetic analyses
of the four reported XP-G/CS individuals who suffered from
severe early onset CS. All four carried mutations that would have
produced truncated XPG proteins (Nouspikel et al, 1997; Okinaka
et al, 1997). In contrast, two sibling XP-G patients with very mild
XP symptoms are able to make full-length XPG containing a single
A792V substitution that severely affects the endonuclease activity of
XPG (Nouspikel and Clarkson, 1994; Nouspikel et al, 1997;
Constantinou et al, 1999). These results suggest that the XP-G/CS
phenotype results from the loss of another important XPG
function. Several converging lines of evidence suggest that this
additional function is an involvement of XPG in the repair of
oxidative DNA damage, both transcription coupled and un-
coupled. At one level, XPG stimulates the activity of NTH1, the
human DNA glycosylase-apurinic (AP) lyase that removes oxidized
pyrimidines from DNA in a distinct base excision repair pathway
(Bessho, 1999; Klungland et al, 1999). Moreover, this stimulation
still occurs with a mutated XPG protein that completely lacks the
NER endonuclease function (Klungland et al, 1999). The loss of
this cofactor activity may account for the less ef®cient removal of
oxidative damage from the genome overall in XP-G/CS patients
(Cooper et al, 1997). Most strikingly, oxidative damage, including
thymine glycol and 8-oxoguanine, is removed by TCR in cells
from XP-G and normal individuals but not from severely affected
XP-G/CS patients (Cooper et al, 1997; Le Page et al, 2000). It is
not yet known how XPG functions in TCR or if it also plays a part
in transcription.
The founding member of the XP-G complementation group
was described over two decades ago (Cheesbrough, 1978; Keijzer
et al, 1979) when the patient, XP2BI, was aged 17 y. She presented
freckling, telangiectasia, pigmentation and atrophy on exposed
parts, bird-like facies, microcephaly, and mental retardation.
Unfortunately, there exist no later clinical records of this patient.
The second XP-G individual, XP3BR, was over 7 y old when
reported (Arlett et al, 1980). In addition to the skin changes typical
of XP, he exhibited severe mental retardation, severe growth
impairment, and dental caries. He died in early adulthood. The
potential connection between XP-G and CS was not appreciated at
the time these patients were reported but their ages indicate that
they did not suffer from the severe early onset form of CS. The
bird-like facies of XP2BI and the dental caries of XP3BR, together
with the growth defects of both individuals, however, suggest that
they might have been affected by a milder form of CS. Here we
report the mutations in the XPG gene of these two patients and the
effects of these mutations on the ability of XPG to act as an
endonuclease in vitro and to repair UV damage in vivo. We discuss
their implications for the clinical symptoms of these two patients
that are intermediate between mild XP and severe XP/CS.
MATERIALS AND METHODS
Cell strains and culture Primary skin ®broblasts were cultured in
minimal essential medium (Seromed, Basel, Switzerland) supplemented
with 15% fetal calf serum, 2 mM L-glutamine, 100 U penicillin per ml,
and 100 mg streptomycin per ml. Cell strains used were XP2BI and
XP3BR (patients), XP124LO and XP125LO (XP-G), XPCS1LV,
XPCS2LV, XPCS1RO, XP20BE, and XPCS1BD (XP-G/CS),
GM02252 (XP-B/CS, from patient XP11BE), and 250BR (normal
control). Lymphoblastoid cells LBL463 from patient XP3BR and Raji
cells were cultured in RPMI (Seromed) supplemented with 10% fetal
bovine serum, glutamine, and antibiotics.
Nomenclature and subcloning XPG mutations are named according
to the recommendations of the Nomenclature Working Group for
human gene mutations (Antonarakis, 1998; den Dunnen and
Antonarakis, 2000). Positions in the cDNA sequence are given from the
initiating ATG with the A denoted +1.
The 2751delA and 2880±2881del mutations found in patient XP3BR
were subcloned as fully sequenced 193 bp BspHI±BbsI fragments into an
otherwise wild-type XPG cDNA in pBluescript II KS. The two
mutations were combined using unique StuI and BglII sites to give the
[2751delA + 2880±2881del] double mutant. The 2573T > C mutation
found in patient XP2BI was similarly subcloned into XPG as a 276 bp
MfeI±StuI fragment. For use in the vaccinia expression system, the
2751delA, 2880±2881del and [2751delA + 2880±2881del] mutations
were transferred into pGEM-XPG (Constantinou et al, 1999) on
1559 bp Bsu36I±NotI fragments. Similarly, a 3386 bp HindIII fragment
containing the 2573T > C mutation and most of the coding sequence
replaced the corresponding fragment of pGEM-U1A-XPG. In all cases,
the presence of the mutations and intact cloning sites were con®rmed
after subcloning. For transfection of lymphoblastoid cells, mutant XPG
cDNA were cloned into the NotI site of the episomal vector EBO-pLPP
(Spickofsky et al, 1990).
RNA extraction, reverse transcription±polymerase chain reaction
(reverse transcription±PCR), and oligonucleotide typing All
protocols have been described previously (Nouspikel et al, 1997). For
oligonucleotide typing, the following g-32P-adenosine triphosphate-
labeled primers were used: 5¢-GACAAAATTCTCTA-3¢ (WT) and 5¢-
GACAAATCTCTAAT-3¢ (DAT) for the 2880±2881del mutation, and
5¢-CGATCTTTTCTGTC-3¢ (WT) and 5¢-CGATCTTTCTGTC-3¢
(DA) for 1494delA.
UV survival assays Semicon¯uent ®broblasts were trypsinized and
resuspended in culture medium to give a concentration of 0.2±1.0 3 104
cells per ml, depending on their growth rate. Four milliliters of
suspension were seeded into each of 12 Petri dishes (6 cm diameter).
After 24 h at 37°C, the cells were UV irradiated at 254 nm in Hanks
buffer (UV ¯uence: 0.125 J per m2 per s) for various times (two dishes
for each dose and four for mock-treated cells). The buffer was replaced
by fresh medium which, in turn, was replaced by fresh medium after
4 d. One day later, when the nonirradiated cells had not yet reached
con¯uence, the medium was replaced by 3 ml of fresh prewarmed
medium containing methyl-3H-thymidine (20 Ci per mM, 5 mCi per
ml) and 20 mM HEPES-KOH (pH 7.3). The cells were incubated at
37°C for 2.5 h, rinsed once with prewarmed PBS then cultured with
4 ml of HEPES medium for a further 01.25 h. The cells were rinsed
with PBS, lyzed with 1 ml of fresh 200 mM NaOH, and 0.85 ml of the
lysis mixture were mixed with 7.5 ml of scintillation ¯uid for
scintillation counting (Hamel et al, 1996).
For UV survival assays of lymphoblasts, the LBL463 cell line was
transfected by electroporation with a Gene Pulser (Bio-Rad) at 250 V,
960 mF in RPMI 1640 medium containing 20 mg recombinant DNA per
ml and 400 mg Escherichia coli tRNA per ml. Transfectants were selected
with increasing doses of hygromycin B (Calbiochem, Lucerne,
Switzerland) up to 200 mg per ml. Selected cells were UV-irradiated as
described. Quadruplet 200 ml samples containing 105 cells were incub-
ated for 46 h at 37°C in 96-well plates. Methyl-3H-thymidine (1 mCi)
was then added to 25 ml medium in each well and incubation was
continued for a further 2 h. The plates were frozen, thawed, and the
lyzed cells were recovered on glass micro®ber ®lters. After thorough
washing, the ®lters were assayed for 3H content by liquid scintillation
counting (Constantinou et al, 1999).
Protein extracts Cells were washed twice in PBS and proteins were
solubilized 30 min at 4°C in a lysis buffer of 50 mM Tris±HCl (pH 7.4),
250 mM NaCl, 5 mM ethylenediamine tetraacetic acid, 0.1% Triton
X-100 supplemented with 0.56 mM phenylmethylsulfonyl ¯uoride, 2 mg
aprotinin per ml, 2 mg leupeptin per ml, and 1 mg pepstatin per ml.
Lysates were centrifuged for 20 min at 14,000 3 g and supernatants were
recovered. In some experiments, to enrich for XPG, (NH4)2SO4 was
added to the extracts. After 20 min on ice, the samples were centrifuged
for 20 min at 14,000 3 g. The pellets were washed with saturated
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(NH4)2SO4, resuspended in 10 mM Tris±HCl (pH 7.5), and precipitated
with 9 vol of 70% acetone, 20% EtOH, 10% 10 mM Tris±HCl (pH 7.5)
at ±20°C. Proteins were then pelleted for 30 min at 14,000 3 g and
4°C, and resuspended in 10 mM Tris±HCl (pH 7.5).
Metabolic labeling Raji and LBL463 cells were rinsed once with PBS
then incubated overnight with labeling medium containing 9 vol RPMI
without methionine and cysteine (Sigma, Buchs, Switzerland), 1 vol
complete RPMI, 10% fetal bovine serum, and 100 mCi per ml EasyTag
Express protein labeling mix (NEN, Perkin-Elmer, Rotkreug,
Switzerland) containing L-35S-methionine and L-35S-cysteine. Cells were
then washed twice in a large volume of cold PBS and lyzed as described
in ``Protein extracts''. Lysates were incubated for 2 h at 4°C with 100 ml
of protein A Sepharose beads (CL-4B, Amersham Phamacia Biotech,
DuÈbendorf, Switzerland) resuspended in NET150NaF buffer containing
50 mM Tris±HCl (pH 8), 150 mM NaCl, 50 mM NaF, and 0.01%
nonidet 40. The beads were removed by centrifugation and the lysates
were incubated a further 2 h with 100 ml of protein A Sepharose. Beads
were removed another time and the supernatants were washed a third
time, overnight at 4°C with 150 ml of protein A Sepharose. These
clearance steps remove most of the endogenous B cell IgG from the
lysates. The supernatants were then incubated overnight at 4°C with or
without 4 ml of the anti-XPG 8H7 monoclonal antibody (Evans et al,
1997). After addition of 50 ml of protein A Sepharose and incubation for
2 h at 4°C, beads were washed four times with 400 ml of NET150NaF.
Twenty microliters of sodium dodecyl sulfate gel loading buffer was then
added and the samples were then heated for 5 min at 95°C. The
supernatants were loaded on a 5% sodium dodecyl sulfate±polyacrylamide
gel. After migration, the gel was ®xed, dried, and exposed for 2 d to
X-ray ®lm.
Expression of mutated XPG proteins Overexpression of proteins
using a recombinant vaccinia virus has been described previously
(Constantinou et al, 1999). Brie¯y, HeLa cells were infected with 5 pfu
per cell of vTF7-3, a recombinant vaccinia virus expressing T7 RNA
polymerase (Fuerst et al, 1986). At 1 h postinfection, the medium was
replaced with a transfection mix comprising minimal essential medium,
5 mg plasmid DNA, and 15 ml TransfectACE (Rose et al, 1991). After
3 h at 33°C, minimal essential medium supplemented with 5% fetal
bovine serum was added and incubation was continued at 33°C. Cells
were harvested 24 h later in PBS, centrifuged at 300 3 g and
resuspended in one pellet vol of buffer A containing 50 mM Tris±HCl
(pH 8), 300 mM NaCl, and 0.1% nonidet 40 supplemented with 10%
glycerol, 1 mM ethylenediamine tetraacetic acid, 1 mM dithiothreitol,
0.1 mM phenylmethylsulfonyl ¯uoride, 2 mg leupeptin per ml, and 1 mg
pepstatin per ml. The suspension was incubated on ice for 30 min then
nuclei were removed from the cytosolic extracts by centrifugation at
14,000 3 g for 20 min.
Western blots Immunoblotting was performed essentially as described
(Nouspikel et al, 1997). Equivalent cell extracts were boiled for 5 min in
sodium dodecyl sulfate gel loading buffer and electrophoresed on 5%
polyacrylamide gels. The proteins were transferred to Immobilon-PVDF
membranes (Millipore, Mont-sur-Lausanne, Switzerland) using a semidry
transfer apparatus (LKB-Instrument AG, Littau-Luzern, Switzerland) at
3 mA per cm2 of membrane for 45 min Membranes were blocked for
1 h in 3% skim milk in 100 mM Tris±HCl (pH 7.5), 0.9% NaCl, 0.05%
Tween 20 (TBS-T) then incubated overnight at 4°C with either the
8H7 monoclonal antibody or a rabbit polyclonal antibody raised against
the N-terminus of XPG (O'Donovan et al, 1994b), both diluted to 1/
200 in 1% skim milk in TBS-T. Blots were washed 3 3 15 min in
TBS-T then incubated for 1 h with a peroxidase-conjugated anti-mouse
or anti-rabbit antibody (Amersham Phamacia Biotech, 1/4000 in 1%
skim milk in TBS-T). After three washes of 15 min each in TBS-T,
signals were detected using ECL chemiluminescence (Amersham
Pharmacia Biotech) and, when necessary, quanti®ed by densitometry
(Molecular Dynamics Inc., DuÈbendorf, Switzerland).
Immunopuri®cation, immunoprecipitation, and endonuclease
assay These procedures have been described previously (Constantinou
et al, 1999). In brief, XPG proteins were immunopuri®ed by mixing
4 ml of 8H7 antibody with appropriate amounts of HeLa extracts.
Volumes were completed to 100 ml with buffer A. After incubation for
1 h at 4°C, the XPG-8H7 antibody complex was coupled with 10 ml of
protein A Sepharose beads for 1.5 h at 4°C. Beads were subsequently
washed twice in 500 ml of buffer A, then twice in 500 ml of buffer B
containing 25 mM HEPES-KOH (pH 6.8), 10% glycerol, 2 mM MgCl2,
and 1 mM dithiothreitol supplemented with 150 mM KCl, 0.4% nonidet
40, 0.1 mM phenylmethylsulfonyl ¯uoride, 2 mg leupeptin per ml, and
1 mg pepstatin per ml, and ®nally resuspended in 20 ml buffer B for use
in the endonuclease assay. The ``bubble'' substrate used in this assay
comprises two partially complementary 90-mer oligonucleotides with a
central 30 nt unpaired region (O'Donovan et al, 1994a; Constantinou
et al, 1999). One strand was previously 5¢-labeled with polynucleotide
kinase and g-32P-adenosine triphosphate. Substrate (0.2±0.5 ng) was
incubated with the immunopuri®ed sample for 3 h at 37°C. Reactions
were stopped by addition of 30 mM ethylenediamine tetraacetic acid,
0.6% sodium dodecyl sulfate, and 0.4 mg per ml proteinase K. After
30 min at 37°C, phenol extraction and ethanol precipitation, samples
were resuspended in formamide dye mix, heated at 95°C and loaded on
to denaturing 12% polyacrylamide gels.
RESULTS
XP2BI and XP3BR ®broblasts are highly UV sensitive The
UV sensitivities of primary ®broblasts from these two patients were
compared with those of ®broblasts from a normal individual, two
XP-G patients: XP124LO and XP125LO (Norris et al, 1987), and
four XP-G/CS patients: XPCS1LV and XPCS2LV (Jaeken et al,
1989; Vermeulen et al, 1993), XP20BE (Moriwaki et al, 1996) and
XPCS1RO, who was previously referred to as 94RD27 (Hamel
et al, 1996; Nouspikel et al, 1997). Figure 1A shows 3H-thymidine
incorporation of the wild-type and mutant ®broblasts 5 d after UV
irradiation. Cells from patients XP124LO and XP125LO (siblings
affected by the same mutations) show only modest UV sensitivity
due to some residual activity of their A792V mutant XPG protein
(Constantinou et al, 1999). In contrast, all four XP-G/CS cells are
highly UV sensitive. They all encode truncated XPG proteins that
presumably are devoid of endonuclease activity (Nouspikel et al,
1997; Okinaka et al, 1997). Figure 1B shows the same experiment
performed on XP2BI and XP3BR ®broblasts. Both ®t into the XP-
G/CS pattern and they behave as if they have little if any XPG
endonuclease activity.
Mutations in the XPG gene of XP2BI For molecular genetic
analysis, total RNA was isolated from XP2BI ®broblasts, reversed
transcribed, and the » 3.6 kb XPG cDNA was ampli®ed by PCR.
The products were cloned in a plasmid vector and several clones
were sequenced. Both XPG alleles carry two known
polymorphisms (Nouspikel and Clarkson, 1994; Emmert et al,
2001): a silent T±C transition at position 138 (H46) and a C to G
transversion at position 3310 (H1104D). One allele contains a
single point mutation, a T±C transition at position 2573, which
replaces leucine 858 with a proline. Its existence was con®rmed by
Figure 1. UV sensitivity of primary ®broblasts from XP-G
patients. Cells were assayed for survival by 3H-thymidine incorporation
5 d after treatment with the indicated UV doses. (A) Wild-type 250BR
control cells are only moderately UV sensitive, whereas cells from four
XP-G/CS patients exhibit strong UV sensitivity (open symbols). Cells
from mildly affected XP-G patients XP124LO and XP125LO show
intermediate sensitivity. (B) The UV sensitivities of XP3BR and XP2BI
®broblasts overlap those of the XP-G/CS cells (lower gray area).
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sequencing XP2BI genomic DNA that revealed the presence of
both C and T at this position (Fig 2A). This leucine is located
within the evolutionary conserved I region that is thought to form
part of the XPG endonuclease active site (Constantinou et al, 1999).
The existence of 2573T > C was also independently con®rmed by
digestion of reverse transcription±PCR and genomic PCR
products with the enzyme BstNI, for which a new site is created
by the mutation (Fig 2C). This allele would also express the
H1104D polymorphism but this is unlikely to have functional
signi®cance because XPG cDNA carrying D1104 can restore UV
resistance to XPG-defective mouse and human cells (MacInnes et al,
1993; Shiomi et al, 1994). Moreover, a recent screen of 91 non-XP
individuals showed D1104 to be » 3-fold more frequent than
H1104 (Emmert et al, 2001).
The other XPG allele in XP2BI contains a 4 nt deletion
(AGGA) from positions 1114 to 1117. This creates a frameshift
resulting in a truncated protein of 376 amino acids, the last ®ve
being unrelated to XPG. The existence of 1114±1117delAGGA
was con®rmed by sequencing XP2BI genomic DNA that revealed
the expected sequence doublets from position 1114 (Fig 2B). The
deletion creates a new site for the restriction enzyme HgaI, which
was experimentally con®rmed by digestion of reverse transcrip-
tion±PCR and genomic PCR products (Fig 2D). In addition, the
same allele carries another silent polymorphism, a C±T transition at
position 960 (D320), as well as an A±G transition at position 2636
that would result in a N879S substitution; however, the protein is
truncated upstream of this point, so presumably this mutation has
no functional consequence. Figure 2E schematizes the mutant
XPG proteins encoded by XP2BI cells.
Mutations in the XPG gene of XP3BR The same procedure
was applied to XP3BR primary ®broblasts and to LBL463
lymphoblastoid cells from this patient. In this case, the two XPG
alleles can be distinguished by the H1104D polymorphism. The
allele encoding an Asp is missing one A residue within an A4
stretch at positions 1491±1494. The resulting frameshift generates a
truncated protein of 521 amino acids, the last 23 being unrelated to
XPG. The existence of this deletion was con®rmed by sequencing
XP3BR genomic DNA that revealed the expected sequence
doublets from position 1491 (Fig 3A), and by hybridization of
XP3BR reverse transcription±PCR and genomic PCR products
with oligonucleotide probes speci®c for the mutated and the wild-
type sequences (Fig 3C).
The other XPG allele in XP3BR lacks one A within an A9
stretch at positions 2743±2751. This results in a truncated protein of
980 amino acids, the last 64 being unrelated to XPG. The existence
of this deletion was con®rmed by sequencing XP3BR genomic
DNA that revealed the expected sequence doublets from position
2743 (Fig 3B). Owing to the length of the A tract, independent
con®rmation of the mutation was not possible by restriction or
differential hybridization analyses, but the 2751delA mutation was
found in 10 independent clones from LBL463 lymphoblasts and in
®ve independent clones from primary ®broblasts. Interestingly, an
intron is located in between the deletion and the termination
codon resulting from the frameshift. The splice donor and acceptor
sites of this intron do not correspond to the canonical GT±AG
consensus sequences, but instead they resemble the motifs found in
a rare class of U12-dependent AT±AC introns (Tarn and Steitz,
1997). The donor site exactly matches the ATATCCTT motif but
the acceptor site contains TGCAT instead of YCCAC (Fig 3E).
This may help to explain the production of a minor alternative
splicing event that removes the ®rst two nucleotides from the
following exon (2880±2881del; Fig 3E). The existence of such
aberrant splicing was con®rmed by hybridization of reverse
transcription±PCR products from XP3BR cells with oligonucleo-
tide probes speci®c for the normal and abnormal splice products
(Fig 3D). For this patient, the combination of this splicing event
with the single nucleotide deletion in position 2751 would restore
the reading frame and thereby generate an almost full-length XPG
protein of 1185, instead of 1186 amino acids. Such a protein would
contain an internal stretch of 44 amino acids unrelated to XPG. For
simplicity, this K917fs962fsX1186 protein is hereinafter referred to
as 917fs962fs. Figure 3F schematizes the mutant XPG proteins
potentially produced in XP3BR cells.
Figure 2. Mutational analysis of XP2BI. (A) A T±C transition at
position 2573 converts a leucine to a proline at residue 858, whereas the
second allele (B) harbors a 4 nt deletion at positions 1114±1117. In both
panels, the wild-type genomic sequence is shown above and the
mutation is shown below the sequence. (C) The 2573 > C mutation
creates a BstNI restriction site that allows the digestion (B) of 186 bp
reverse transcription±PCR products (black arrow) into 132 bp and 54 bp
fragments (open arrows). The genomic PCR products are correspondingly
longer because of the presence of an intron between the PCR primers
(panel c, bottom). The XP2BI patient (2BI) is heterozygous for this
2573 > C mutation that is absent from another individual (95 for
95RD112 ®broblasts from XP-G patient XPCS1BD). (D) The 1114±
1117delAGGA mutation introduces a new HgaI site allowing the
digestion (H) of a 559 bp fragment (555 bp for XP2BI; open arrow) into
353 and 206 bp fragments (black arrows). In the genomic PCR products,
the presence of a short intron generates a 860 bp fragment (open arrow)
that is cleaved by HgaI into 654 and 206 bp fragments (black arrows). The
patient is heterozygous for this 4 nt deletion that does not occur in
XP3BR (3BR) cells. ±, undigested; L, length markers of HaeIII digested
pBluescript SK±. (E) Schematic diagram of wild-type XPG and of
mutant XPG proteins encoded by XP2BI ®broblasts. N, I, C, and NLS
indicate the conserved N-terminal, internal and basic C-terminal regions,
and putative nuclear localization signal, respectively. Nomenclature
follows current recommendations (Antonarakis, 1998; den Dunnen and
Antonarakis, 2000).
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Mutant 917fs962fs XPG protein is expressed in XP3BR
cells To determine if the predicted 917fs962fs XPG protein is
indeed produced and stable in XP3BR cells, western blots were
done on LBL463 lymphoblast extracts from this patient. As shown
previously for XP-G patients XP124LO and XP125LO, it is
dif®cult to detect a decreased endogenous level of XPG in crude
extracts of lymphoblasts (Nouspikel et al, 1997). Therefore, two
approaches were taken to enhance the detection of XPG. In the
®rst, extracts from XP3BR (LBL463) and from an XP-B/CS
patient (as XPG positive control) were precipitated with
ammonium sulfate before electrophoresis to increase the ratio of
XPG to total protein. Wild-type XPG is readily detected in the
enriched XP-B/CS extract (Fig 4A) with a polyclonal rabbit
antibody to the N-terminus of XPG (O'Donovan et al, 1994b).
XPG migrates near the 205 kDa marker (Nouspikel et al, 1997),
probably because of its acidic nature (Scherly et al, 1993). A faint
band of comparable length is also found in the enriched XP3BR
extracts (Fig 4A), indicating the presence of the 917fs962fs XPG
protein. In the second approach, LBL463 and wild-type Raji
lymphoblasts were labeled with 35S-methionine and 35S-cysteine
and the cell extracts were then immunoprecipitated with 8H7, a
mouse monoclonal antibody to XPG (Evans et al, 1997). XPG
bands of comparable length are detectable in both extracts after
addition of the antibody (Fig 4B). We conclude that alternative
splicing of pre-mRNA from one XPG allele permits production of
the almost full-length 917fs962fs XPG protein in XP3BR
lymphoblasts. Presumably this is also true for other cell types but
we have not been able to demonstrate XPG in XP3BR ®broblasts
because of the lower ratio of XPG to total protein in this cell type
(data not shown). We have also not been able to detect the L858P
XPG protein in extracts of XP2BI ®broblasts and, unfortunately,
no lymphoblastoid cell line exists for this patient.
Mutant L858P and 917fs962fs XPG proteins have severely
diminished endonuclease activity To test intrinsic XPG
endonuclease activity, wild-type XPG, the L858P and 917fs962fs
mutants, and CSB as a negative control were overexpressed in
HeLa cells using a vaccinia virus-based expression system
(Constantinou et al, 1999). As shown by western blotting
(Fig 5C), the amount of endogenous HeLa XPG in the extracts
(CSB lane) is negligible relative to the overexpressed wild-type and
mutant XPG proteins. Equivalent 1:2:3 amounts of wild-type and
mutant proteins were then mixed with the 8H7 anti-XPG
Figure 4. Detection of the K917fs962fsX1186 XPG protein in
XP3BR lymphoblasts. (A) Lymphoblastoid cells from XP3BR
(LBL463) and XP11BE (an XP-B/CS patient used as a control) were
lyzed and submitted to western blotting using a polyclonal antibody to
the N-terminus of XPG. Lanes 1 and 4 contained 200 mg of total
protein. For lanes 2 and 5, and lanes 3 and 6, 400 mg total proteins were
submitted to 40% or 50% ammonium sulfate precipitation, respectively,
prior to gel electrophoresis. (B) LBL463 and control Raji lymphoblasts
were labeled overnight with L-35S-methionine and L-35S-cysteine,
protein extracts were prepared and immunoprecipitated with (+) or
without (±) the 8H7 anti-XPG monoclonal antibody prior to gel
electrophoresis. The arrows in both panels show the locations of the 1186
amino acid wild-type XPG and the 1185 amino acid mutant protein.
Figure 3. Mutational analysis of XP3BR. (A)
Deletion of one A in a stretch of four at positions
1491±1494 (1494delA) generates a frameshift and
a truncated XPG protein of 521 amino acids
(D499fsX522). (B) Deletion of one A in a stretch
of nine at positions 2743±2751 (2751delA)
generates a frameshift and a truncated protein of
980 amino acids (K917fsX981). In both panels,
the wild-type genomic sequence is shown above
and the mutation is shown below the sequence.
(C) Con®rmation of 1494delA mutation by
hybridization of reverse transcription±PCR
(mRNA) and genomic PCR (DNA) products
with oligonucleotide probes speci®c for the
mutated (DA) or wild-type (WT) sequences.
Plasmid DNA with or without the mutation were
used to con®rm the speci®cities of the probes. (D)
Con®rmation of the aberrantly spliced 2880±
2881del mutation using the same technique and
appropriate DAT oligonucleotide probe. (E)
Exon±intron 13 boundaries in wild-type XPG and
in the 2751delA allele from XP3BR. The
combination of the 2751delA and 2880±2881del
deletions generates a 1185 residue XPG protein
containing an internal stretch of 44 aberrant
amino acids (K917fs962fsX1186). (F) Summary of
XPG proteins encoded by XP3BR cells.
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monoclonal antibody coupled to protein A Sepharose beads, and
the immobilized XPG proteins were incubated with a radiolabeled
bubble substrate as previously described (Constantinou et al, 1999).
Structure-speci®c endonuclease activity releases a major labeled
61 nt product from this substrate (O'Donovan et al, 1994a). As
expected, the overexpression of wild-type XPG protein results in a
much higher activity than that of the endogenous XPG (compare
lanes 4±6 with lanes 1±3, Fig 5B). In contrast, neither the L858P
nor 917fs962fs mutant protein shows any detectable activity in this
in vitro assay, despite being more abundant than the endogenous
XPG protein (compare lanes 7±9 and lanes 10±12 with lanes 1±3,
Fig 5B). We conclude that, in isolation, these mutant XPG
proteins are unable to act as structure-speci®c endonucleases.
To investigate the consequences of the mutations on in vivo
activity, XPG cDNA containing the wild-type sequence,
2573T > C or the double mutation [2751delA + 2880±2881del]
were cloned into an episomal vector and were electroporated into
LBL463 lymphoblastoid cells from patient XP3BR. As the
2751delA mutation and 2880±2881del alternative splice can
occur independently, they were also cloned separately and
introduced into LBL463 cells. Stable transfectants were selected
and cell survival was assayed by 3H-thymidine incorporation 48 h
after UV treatment. Cells expressing the 2751delA or 2880±
2881del frameshift mutations are extremely UV sensitive, just as
sensitive as cells transfected with the vector alone (Fig 6). The
combination of both mutations, which permits expression of almost
full-length XPG, does not improve UV resistance; if anything, it
reduces it even further (Fig 6). Transfectants carrying the
2573T > C transition are slightly more UV resistant than the
other mutants but at 10 J per m2 are at least 50-fold more UV
sensitive than transfectants expressing wild-type XPG (Fig 6).
To assess the production and stability of these various XPG
proteins, western blots were done on the LBL463 transfectants.
Both wild-type XPG and the 917fs962fs mutant encoded by
[2751delA + 2880±2881del] cDNA are produced in normal
amounts in the relevant transfectants (data not shown); however,
we have never been able to detect L858P protein in 2573T > C
transfectants (data not shown), even though L858P is readily
detected in HeLa cells with the vaccinia virus-based expression
system (Fig 5C). A possible reason for this apparent discrepancy is
discussed below. We conclude that the key full-length and almost
full-length mutant XPG proteins produced in XP2BI and XP3BR
cells, L858P and 917fs962fs, respectively, would severely com-
promise in vivo NER activity.
DISCUSSION
The molecular genetic evidence in this study shows that the ®rst
two reported XP-G patients, XP2BI and XP3BR, are compound
heterozygotes with different mutations in each XPG allele. Table I
summarizes the mutations and polymorphisms found in each allele,
together with their resulting XPG protein products. In XP3BR,
one allele generates a 521 amino acid protein instead of full-length
XPG of 1186 amino acids (Fig 3). This truncated protein lacks the
highly conserved I-region that is thought to juxtapose with the
N-region to form the active site of this structure-speci®c
endonuclease (Constantinou et al, 1999). Although it was not
tested for activity, this protein is expected to be nonfunctional
because a less severe truncation inactivates NER in vivo (Nouspikel
and Clarkson, 1994).
The second XPG allele in XP3BR produces a truncated protein
of 980 amino acids that retains both the conserved N- and
I-regions; however, XP-G transfectants expressing this mutated
allele are still extremely UV sensitive (Fig 6). This indicates that
this mutant XPG protein is unable to act ef®ciently in NER, for
which there are several possible explanations. Having lost the
nuclear localization signal near the C-terminus (Fig 3), it may not
Figure 5. The full-length and almost full-length XPG proteins
produced in XP2BI and XP3BR cells are devoid of intrinsic
structure-speci®c endonuclease activity. (A) Schematic repre-
sentation of the pull down endonuclease assay. (C) After expression in
vTF7-3-infected HeLa cells transfected with cDNA for CSB as a
negative control, wild-type XPG, or the two mutated XPG proteins,
lysates were electrophoresed on a 5% polyacrylamide gel, blotted and
probed with the mouse anti-XPG monoclonal antibody 8H7. (B) The
autoradiograph in panel C was scanned to evaluate the amount of XPG
relative to the total protein concentration in each HeLa extract.
Equivalent 1:2:3 ratios of XPG were immunopuri®ed from appropriate
amounts of the extracts and incubated for 3 h with a bubble substrate 5¢-
labeled on one strand. The products of the endonuclease reactions were
analyzed on a denaturing 12% polyacrylamide gel.
Figure 6. XPG cDNA are unable to restore UV resistance to
XPG-defective cells. Lymphoblastoid LBL463 cells were transfected
with wild-type or mutant XPG cDNA subcloned in the episomal EBO-
pLPP vector, or with the vector alone. The cells were then assayed for
survival by 3H-thymidine incorporation 48 h after treatment with the
indicated UV doses.
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be able to enter the nucleus. Even if transported to the nucleus, an
altered conformation may prevent it being positioned correctly in
the NER incision complex and/or prevent it functioning as an
endonuclease despite its retention of the N- and I-regions. In
isolation, this truncated protein has no detectable structure-speci®c
endonuclease activity (Fig 5), which suggests the likelihood of at
least this third possibility.
The second XPG allele from XP3BR also generates another
mutated form of XPG through alternative splicing of a rare AT±AC
intron (Tarn and Steitz, 1997). The combination of the single
nucleotide deletion 2751delA and the loss of the ®rst two
nucleotides from the downstream exon 14 (Emmert et al, 2001;
Pigni, 2001) restores the open reading frame and produces a protein
of 1185 amino acids, 44 of which are unrelated to XPG (Fig 3).
This mutant 917fs962fs protein retains the N- and I-regions, the
nuclear localization signal, and the basic C-terminus of XPG;
however, it has no detectable intrinsic structure-speci®c endo-
nuclease activity (Fig 5), presumably due to the presence of non-
XPG sequences near the C-terminal boundary of the I-region.
Consistent with its lack of activity in vitro, XP-G transfectants
expressing the mutant 917fs962fs protein are at least as UV sensitive
as XP-G cells transfected with the vector alone (Fig 6). We
conclude that, although this almost full-length mutant XPG protein
is stably expressed in XP3BR (Fig 4), it has little if any NER
activity, thereby contributing to the UV sensitivity of cells from this
patient (Fig 1).
In XP2BI, one XPG allele is missing the four nucleotides from
positions 1114 to 1117. This causes a frameshift that results in a
protein of 376 amino acids, the last ®ve being unrelated to XPG
(Fig 2). This is an even more severe truncation than the shortest
XPG protein produced in XP3BR and it is therefore expected to
be inactive. This allele also encodes a N879S substitution that
presumably is without functional signi®cance because it is located
C-terminal to the truncation.
The second and more interesting XPG allele from XP2BI
contains the H1104D polymorphism and a single pyrimidine
transition that results in a L858P substitution in the conserved
I-region (Fig 2). In isolation, this mutant XPG protein exhibits no
structure-speci®c endonuclease activity (Fig 5), but XP-G trans-
fectants expressing the L858P protein are slightly more UV resistant
than transfectants carrying the EBO-pLPP vector alone (Fig 6).
This suggests that the L858P XPG protein does have some very
slight endonuclease activity but that the presence of other NER
components is required for this to be revealed. XPG proteins with
deliberately created acidic substitutions in the N- and I-regions
(D77E and E791D, respectively) behave in a similar way
(Constantinou et al, 1999).
The mutant L858P XPG protein is readily detected when
expressed in HeLa cells with the vaccinia virus system (Fig 5C) but
we have never been able to ®nd it by western blotting in
transfected XP-G lymphoblasts (data not shown). These two cell
systems are very different, however. The vaccinia system generates
huge amounts of protein (Fig 5C) and, moreover, in a context in
which much of the normal cell machinery is short-circuited by the
virus. In particular, it is likely that normal degradative as well as
synthetic pathways are defective. In contrast, wild-type protein
levels are produced from the SV40 early promoter in the XPG
EBO-pLPP recombinants transfected into XP-G lymphoblasts (data
not shown). Together, these results suggest that the mutant L858P
protein does have some slight residual NER endonuclease activity
but that it is also less stable than wild-type XPG. The net result is
that this full-length mutant XPG protein contributes to the severe
UV sensitivity of XP2BI cells (Fig 1).
Four mutated forms of XPG thus contribute to the XP clinical
phenotypes of patients XP2BI and XP3BR: two truncated
proteins, a stable almost full-length protein containing an internal
stretch of non-XPG residues, and full-length XPG of reduced
stability containing an amino acid substitution in the conserved
I-region. The clinical symptoms may arise through the suboptimal
presence of these proteins, particularly during early development, as
well as their reduced biologic activity. In addition, polymorphisms
in other genes may contribute to the diverse clinical manifestations
of these two patients. None of the mutated forms of XPG can act
ef®ciently as the 3¢ endonuclease in NER. These four proteins can
thus account for the severe UV sensitivities of XP2BI and XP3BR
®broblasts, which clearly overlap those of XP-G/CS rather than
XP-G cells (Fig 1); however, neither patient was affected by early
onset CS, although there are hints that both may have been affected
by a milder form of CS. Recently, XP2BI and XP3BR ®broblasts
have been found to be capable of limited TCR of oxidative DNA
damage (Le Page et al, 2000). Our results suggest that the L858P
protein in XP2BI and the almost full-length 917fs962fs XPG
protein in XP3BR are responsible for this activity, and that as a
consequence they prevent the development of severe early onset
CS symptoms in these patients.
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Table I. Polymorphisms, mutations, and XPG proteins in XP2BI and XP3BR
Patient Allelea Polymorphism Mutation Amino acid change XPG protein products





3310C > G H1104Dd
2 138T > C Silent R372fsX377
960C > T
1114±1117delAGGAb




3310C > G (H1104D)e
XP3BR 1 1494delA D499fsX522 D499fsX522








aAlleles are numbered arbitrarily.
bCon®rmed at RNA level.
cRestores the reading frame downstream from the frameshift mutation.
dD is most frequently found at this position (Emmert et al, 2001).
eDownstream from the truncation.
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